Impact of BRCA1/2 mutations status on patient reported outcomes in HER2- advanced breast cancer: Results from a multi-country real-world study

Date 03 May 2019
Event ESMO Breast Cancer 2019
Session Poster lunch
Topics Aetiology, Epidemiology, Screening and Prevention
Breast Cancer
Hereditary Syndromes
Presenter Alex Rider
Citation Annals of Oncology (2019) 30 (suppl_3): iii47-iii64. 10.1093/annonc/mdz100
Authors A. Rider1, R.G..W. Quek2, K. Lewis3, J. Kemp1, A. Niyazov4
  • 1Oncology, Adelphi Real World, SK10 5JB - Bollington/GB
  • 2Health Economics & Outcomes Research, Pfizer Inc., 94105 - San Francisco/US
  • 3Oncology, Adelphi Real World, Bollington/GB
  • 4Health Economics & Outcomes Research, Pfizer, New York/US

Abstract

Background

Limited information is available on the effect of BRCA1/2 mutations on patient reported outcomes (PROs). This multi-country study assesses the impact of BRCA1/2 mutation status on patient demographics, cancer-related and breast cancer specific PROs in women with human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).

Methods

Oncologists extracted data from patient charts in adult women with HER2- ABC across the US and the United Kingdom, Spain, Germany, France and Italy (EU5) via the Adelphi Advanced Breast Cancer Disease Specific Program in 2017. A subset of patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) and the breast cancer module QLQ-BR23. Patients were categorized into 2 mutually exclusive cohorts; BRCA1/2 mutations (BRCAm) and BRCA wild type (BRCAwt). Differences in patient demographics were compared using t-tests and Pearson’s Chi-squared tests. PROs were compared utilizing inverse probability weighted regression adjustment across multiple potential confounders.

Results

Overall 199 patients participated; (BRCAm n = 37, BRCAwt n = 162). Patients with BRCAm were significantly younger (50.3 vs. 55.4 years old), [P = 0.018] and more likely have a family history of breast or ovarian cancer (43% vs. 22%), [P = 0.003] relative to BRCAwt. Significantly worse scores in role functioning (44.9 vs. 57.9), [P = 0.002] and dyspnea (47.7 vs. 37.0), [P = 0.012] were observed in patients with BRCAm relative to BRCAwt. No statistically significant differences in other EORTC PRO scales were observed.

Conclusions

In this study of adult women with HER2- ABC, patients with BRCAm were significantly younger and more likely to have a family history of breast or ovarian cancer than BRCAwt. Patients with BRCAm reported significantly worse role functioning and dyspnea suggesting that BRCAm targeted treatment options leading to PROs improvements in these patients are needed.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Pfizer.

Funding

Pfizer.

Disclosure

A. Niyazov: Employee, stockholder: Pfizer. R.G.W. Quek: Employee: Pfizer Inc.; Stock ownership: Pfizer Inc., Amgen Inc. All other authors have declared no conflicts of interest.